CMIC CMO USA Corporation is a prominent member of the CMIC Group, Japan's first and largest clinical Contract Research Organisation (CRO) providing comprehensive services ranging from preclinical to clinical operations, drug development, manufacturing, sales, and post-market support. With facilities in the United States, Japan, and Asia, CMIC Group boasts a robust workforce of over 7,000 employees globally. The company operates an FDA-registered facility located near Princeton, NJ, that specialises in formulation development and Good Manufacturing Practice (GMP) commercial manufacturing. CMIC CMO USA is a contract pharmaceutical company renowned for its solid dosage form development and manufacturing services, particularly in controlled release technologies. From initial product development stages through to commercial production, CMIC (pronounced si-mik) employs state-of-the-art technologies and prioritises customer service, effectively catering to the strategic needs of its clients.

Services include:
- 505(b)(2)
- Accelerated Stability Studies
- Analytical Services
- Blending
- Chromatography
- Chemistry (CMC)
- Manufacturing
- Contract Development and Manufacturing (CDMO)
- Contract Manufacturing (CMO)
- Dissolution Testing
- Dosage Form Development
- Encapsulation
- Filling
- Capsule
- Fluid Bed Processing
- Process Development
- Formulation Development
- Controlled Release
- Granulation
- Lot Release Testing
- Clinical Trial Materials
- Generics
- Oral Drug Delivery
- OTC
- Powders
- Non-Sterile
- Solid Dosage
- Sustained Release
- Tablets
- Mixing & Blending
- Preformulation
- Process R&D
- Process Validation Studies
- Quality QA/QC
- Scale-Up
- Stability Studies
- Stability
- ICH
- Sustained Release Delivery Systems
- Tablet Coating
- Technology Transfer
- Validation

In conclusion, CMIC stands out as a leading supplier to the pharmaceutical industry, delivering a wide range of services that cater to diverse drug development needs. For further information, please visit en.cmicgroup.com.